Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell · Charité - Universitätsmedizin Berlin · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
214
total citations
- FWCI
- 31.01
- Percentile
- 100%
- References
- 39
Citations per year
Authors
9- IKInder Kaul
- SSSharon Sawchak
- CUChristoph U. Correll
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Charité - Universitätsmedizin Berlin, Zucker Hillside Hospital
- RKRishi Kakar
Segal Institute for Clinical Research
- ABAlan Breier
Indiana University School of Medicine, Indiana University – Purdue University Indianapolis
Topics & keywords
Topics
Keywords
- Placebo
- Tolerability
- Schizophrenia (object-oriented programming)
- Antipsychotic
- Adverse effect
- Medicine
- Positive and Negative Syndrome Scale
- Agonist
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.